Merck’s Ebola Vaccine Found to Be Effective by Expert Panel

The vaccine was 100 percent effective when it was tested on more than 4,000 people who were in close contact with Ebola patients in the African nation of Guinea, according to a study published today in the Lancet medical journal. The trial of the vaccine, called Ebola ca Suffit -- “Ebola, that’s enough” in French -- began on March 23.

http://www.bloomberg.com

Interim results from the Guinea ring vaccination cluster-randomised trial (Lancet Study PDF)

Interpretation: The results of this interim analysis indicate that rVSV-ZEBOV might be highly efficacious and safe in preventing Ebola virus disease, and is most likely effective at the population level when delivered during an Ebola virus disease outbreak via a ring vaccination strategy.

www.thelancet.com
New Ebola Vaccine Has '100 Percent' Effectiveness In Early Results

The trial was called Ebola ça Suffit – French for "Ebola that's enough." Funded by the World Health Organization and other groups, it started in April and ended on July 20, relying on participants who consented to be part of the trial.

www.npr.org